amantadine has been researched along with ribavirin in 265 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 56 (21.13) | 18.7374 |
| 1990's | 29 (10.94) | 18.2507 |
| 2000's | 113 (42.64) | 29.6817 |
| 2010's | 63 (23.77) | 24.3611 |
| 2020's | 4 (1.51) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; De Clercq, E; Golankiewicz, B; Ikeda, S; Januszczyk, P | 1 |
| De Clercq, E; Foscolos, GB; Fytas, G; Ikeda, S; Kolocouris, A; Kolocouris, N; Marakos, P; Pouli, N | 1 |
| Andrei, G; Balzarini, J; De Clercq, E; Foscolos, GB; Fytas, G; Kolocouris, A; Kolocouris, N; Neyts, J; Padalko, E; Snoeck, R | 1 |
| Balick, M; Chen, JL; Jolad, SD; Kernan, M; Nanakorn, W; Rozhon, E; Sendl, A; Stoddart, C | 1 |
| Balick, MJ; Blanc, P; Chen, JL; Jolad, SD; Kernan, MR; Murphy, JT; Nanakorn, W; Rozhon, EJ; Sendl, A; Stoddart, CA | 1 |
| De Clercq, E; Foscolos, GB; Fytas, G; Kolocouris, A; Kolocouris, N; Mavromoustakos, T; Tataridis, D | 1 |
| De Clercq, E; Foscolos, GB; Fytas, G; Kolocouris, A; Kolocouris, N; Neyts, J; Stamatiou, G | 1 |
| De Clercq, E; Foscolos, GB; Fytas, G; Kolocouris, A; Kolocouris, N; Neyts, J; Padalko, E; Stylianakis, I | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| De Clercq, E; Foscolos, GB; Fytas, G; Kelly, JM; Kolocouris, N; Naesens, L; Prathalingham, SR; Zoidis, G | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| De Clercq, E; Gawin, R; Koszytkowska-Stawińska, M; Naesens, L | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| De Clercq, E; Kolocouris, N; Naesens, L; Zoidis, G | 1 |
| Balzarini, J; Brancale, A; Cirilli, R; Coluccia, A; Giordano, C; La Regina, G; La Torre, F; Lavecchia, A; Maga, G; Novellino, E; Piscitelli, F; Samuele, A; Sansone, A; Silvestri, R; Zanoli, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Batta, G; Herczegh, P; Kéki, S; Komáromi, I; Mándi, A; Naesens, L; Ostorházi, E; Pintér, G; Röth, E; Rozgonyi, F; Sztaricskai, F; Takács-Novák, K | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Batta, G; Bereczki, I; Boda, Z; Herczegh, P; Naesens, L; Ostorházi, E; Otvös, R; Pintér, G; Roth, E; Rozgonyi, F; Szarvas, M; Sztaricskai, F | 1 |
| De Clercq, E; Ganguly, S; Kumar, KS; Veerasamy, R | 1 |
| De Clercq, E; Kelly, JM; Kolocouris, N; Naesens, L; Prathalingam, SR; Zoidis, G | 1 |
| Balzarini, J; De Clercq, E; Dewan, SK; Kumar, P; Narasimhan, B; Pannecouque, C; Yadav, S | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Balzarini, J; Bharatam, PV; Chibale, K; Kaur, H; Little, S; Singh, K | 1 |
| Batta, G; Bereczki, I; Borbás, A; Fejes, Z; Herczegh, P; Kiss-Szikszai, A; Naesens, L; Ostorházi, E; Rőth, E; Rozgonyi, F; Sipos, A; Török, Z | 1 |
| Cesur, N; Cesur, Z; Göktaş, F; Naesens, L; Vanderlinden, E | 1 |
| Batta, G; Bereczki, I; Borbás, A; Herczegh, P; Jóna, I; Kéki, S; Máté, G; Naesens, L; Ostorházi, E; Rőth, E; Rozgonyi, F; Sipos, A; Vanderlinden, E | 1 |
| Balzarini, J; Chibale, K; Kaur, H; Singh, K | 1 |
| Balzarini, J; Singh, K | 1 |
| Barniol-Xicota, M; DeGrado, WF; Lamb, RA; Ma, C; Naesens, L; Pinto, LH; Rey-Carrizo, M; Torres, E; Vázquez, S; Wang, J; Wu, Y | 1 |
| Fernández, R; Font-Bardia, M; Miquet, S; Naesens, L; Torres, E; Vanderlinden, E; Vázquez, S | 1 |
| Batta, G; Bereczki, I; Borbás, A; Dobray, L; Herczegh, P; Kéki, S; Kicsák, M; Naesens, L; Nikodém, ÉN; Ostorházi, E; Rozgonyi, F; Vanderlinden, E | 1 |
| Chen, X; Lin, W; Liu, D; Proksch, P; Si, L; Zhang, L; Zhou, D | 1 |
| Batta, G; Bereczki, I; Borbás, A; Fizil, Á; Herczegh, P; Komáromi, I; Kurtán, T; Mándi, A; Naesens, L; Ostorházi, E; Rőth, E; Rozgonyi, F; Sipos, A; Sztaricskai, F; Vanderlinden, E | 1 |
| Lin, W; Liu, D; Niu, S; Shao, Z; Si, L; Wang, S; Zhang, L; Zhang, Z; Zhou, A; Zhou, D | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chizhov, AO; Geisman, AN; Khandazhinskaya, AL; Kochetkov, SN; Naesens, L; Novikov, MS; Ozerov, AA; Pannecouque, C; Seley-Radtke, KL; Valuev-Elliston, VT | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Cichero, E; Costi, MP; Gazzarrini, S; Loddo, R; Moroni, A; Naesens, L; Santucci, M; Tasso, B; Tonelli, M | 1 |
| Barniol-Xicota, M; Caffrey, M; Codony, S; Ginex, T; Leiva, R; Luque, FJ; Montes, M; Naesens, L; Vanderlinden, E; Vázquez, S | 1 |
| Andrei, G; Pertusati, F; Pileggi, E; Schols, D; Serpi, M; Snoeck, R | 1 |
| Cichero, E; Costi, MP; Francesconi, V; Giordanetto, F; Giovannini, L; Naesens, L; Santucci, M; Tonelli, M | 1 |
| Orshanskaya, IR; Salakhutdinov, NF; Semenova, MD; Shtro, AA; Sokolova, AS; Yarovaya, OI; Zarubaev, VV | 1 |
| Batta, G; Borbás, A; Csávás, M; Herczegh, P; Kelemen, V; Le Thai, S; Naesens, L; Rőth, E; Stevaert, A; Szűcs, Z; Vanderlinden, E | 1 |
| Bormotov, NI; Dorovatovskii, PV; Gatilov, YV; Khrustalev, VN; Kovaleva, KS; Novikov, RA; Salakhutdinov, NF; Shishkina, LN; Yarovaya, OI; Zarubaev, VV; Zubkov, FI | 1 |
| Barbier, J; Cintrat, JC; Davey, RA; Gillet, D; Kali, S; Noël, R; Pons, V; Popoff, MR; Shtanko, O; Tordo, N; Wu, Y | 1 |
| Andrei, G; Cazin, I; Harej, A; Klobučar, M; Macan, AM; Pavelić, K; Pavelić, SK; Raić-Malić, S; Schols, D; Snoeck, R; Stepanić, V | 1 |
| Borisevich, SS; Lantseva, K; Mainagashev, IY; Salakhutdinov, NF; Shtro, AA; Sokolova, AS; Volobueva, AS; Yarovaya, OI; Zarubaev, VV | 1 |
| Çapan, G; Cihan-Üstündağ, G; Naesens, L; Ozkirimli, E; Persoons, L; Vanderlinden, E; Zopun, M | 1 |
| Balzarini, J; De Clercq, E; Karki, SS; Kulkarni, AA; Kumar, S; Veliyath, SK | 1 |
| Duan, Z; Gu, Q; Li, D; Li, J; Liu, Y; Wang, W; Wu, G; Yang, S; Yu, G; Yu, R; Yu, Y; Zhu, T | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| James, DG | 1 |
| Luby, JP | 1 |
| Chang, TW; Snydman, DR | 1 |
| De Clercq, E | 2 |
| St Geme, JW | 1 |
| Dussaix, E; Tournier, P | 1 |
| Arroyo, M; Reed, SE | 1 |
| Diana, GD; Pancic, F | 1 |
| Bauer, DJ; Tisdale, M | 2 |
| Oxford, JS; Schild, GC | 1 |
| ter Meulen, V | 1 |
| Berendt, RF; Scott, GH; Stephen, EL | 1 |
| Cohen, A; Khakoo, R; Sigel, M; Togo, Y; Waldman, R | 1 |
| Hermans, PE | 1 |
| Spertzel, RO; Stephen, EL; Walker, JS | 1 |
| Couch, RB; Jackson, GG | 1 |
| O'Connor, TE | 1 |
| Gustafson, DP | 1 |
| Oxford, JS | 1 |
| Newell, PM; Van Voris, LP | 1 |
| Hayden, FG | 5 |
| Gilbert, BE; Knight, V | 1 |
| Bean, B | 1 |
| Cunningham, AL | 1 |
| Bryson, YJ | 1 |
| Hayden, FG; Sperber, SJ | 1 |
| Johnson, DC | 1 |
| Steele, RW | 1 |
| Dolin, R | 1 |
| Ikeda, S; Mori, K; Nishimura, C | 1 |
| Hansson, BG; Nordenfelt, E; Oberg, B; Widell, A | 1 |
| Gross, PA; Reines, ED | 1 |
| Carpenter, RJ; Faro, S; Kirshon, B; Samo, TC; Zurawin, RK | 1 |
| Cockerill, FR; Hermans, PE | 2 |
| Cates, KL | 1 |
| Nankervis, GA | 1 |
| Chonmaitree, T; Truant, AL | 1 |
| Galbraith, AW | 1 |
| Alaghamandan, H; Call, EW; Cook, PD; Huffman, JH; Robins, RK; Sidwell, RW | 1 |
| Adamczyk, B; Heider, H; Richter, B | 1 |
| Cameron, RW; Couch, RB; Greggs, SE; Knight, V; McClung, HW; Quarles, JM; Waters, BK; Wilson, SZ; Zerwas, JM | 1 |
| Nicholson, KG | 2 |
| Jackson, GG | 1 |
| Galbraith, A; Oxford, JS | 1 |
| Galasso, GJ | 1 |
| Amato Neto, V; Barone, AA | 1 |
| Douglas, RG | 1 |
| White, DO | 1 |
| Togo, Y | 1 |
| Burlington, DB; Meiklejohn, G; Mostow, SR | 1 |
| Boyd, MR; Browne, MJ; Moss, MY | 1 |
| Couch, RB; Drake, S; Knight, V; Wilson, SZ; Wyde, PR | 1 |
| Cote, KM; Douglas, RG; Hayden, FG | 1 |
| Embrey, RP; Geist, LJ | 1 |
| Dempsey, MH; Penn, CR; Ryan, DM; Ticehurst, J | 1 |
| Morris, DJ | 1 |
| Mahmood, W; Sacks, SL | 1 |
| Freymuth, F; Vabret, A | 1 |
| Renner, EL | 1 |
| Margo, KL; Shaughnessy, AF | 1 |
| Hermann, R | 1 |
| Mossad, SB | 1 |
| Foster, GR | 1 |
| Reina, J | 1 |
| Bolondi, L; Brillanti, S; Di Tomaso, M; Foli, M; Gramantieri, L; Masci, C | 1 |
| Marcellin, P | 1 |
| Keating, MR | 1 |
| Bekkering, FC; Brouwer, JT; Schalm, SW; van Rossum, TG | 1 |
| McHutchison, J; Pianko, S | 1 |
| Denham, C; Khalili, M; Perrillo, R | 1 |
| Main, J; Thomas, HC; Wright, M | 1 |
| Bolondi, L; Brillanti, S; Foli, M; Levantesi, F; Masi, L | 1 |
| Glaser, D | 1 |
| Carlsson, T; Lindahl, K; Reichard, O; Schvarcz, R; Shev, S; Uhnoo, I; Wejstal, R | 1 |
| Balija, M; Bingulac-Popovic, J; Drazic, V; Grahovac, B; Grgicevic, D; Hrstic, I; Ostojic, R; Vucelic, B | 1 |
| Barnes, DS; Boparai, N; Brand, E; Carey, WD; Easley, K; Gramlich, T; Hodnick, S; McCullough, AC; Mullen, KD; Younossi, ZM; Zakko, W | 1 |
| Boudjema, H; Cadranel, JF; Caron, C; Cazier, A; Coutarel, P; Delacour, T; Di Martino, V; Dumouchel, P | 1 |
| Berg, T; Hopf, U; Naumann, U; Wiedenmann, B | 1 |
| Fontaine, H; Pol, S; Vallet-Pichard, A | 1 |
| Balestra, V; Brizzolara, R; Campo, N; Giusto, R; Grasso, A; Picciotto, A; Sinelli, N; Torre, F | 1 |
| Chawla, A; Chung, RT; Contreras, AM; He, W; Saquib, A; Schmidt, EV; Wang, TC; Xavier, RJ | 1 |
| Shiffman, ML | 2 |
| Andreone, P; Bernardi, M; Biselli, M; Cavallari, A; Cursaro, C; D'Errico, A; Di Giammarino, L; Galli, S; Gramenzi, A; Grazi, GL; Jovine, E; Mazziotti, A | 1 |
| Rodés, J; Sánchez Tapias, JM | 1 |
| Koczorek, M | 1 |
| Lombraña, JL; Pérez-Alvarez, R; Pérez-López, R; Rodrigo, L; Rodríguez, M | 1 |
| Bellobuono, A; Idéo, G | 1 |
| García Buey, L; Moreno Monteagudo, JA; Moreno Otero, R | 1 |
| García Buey, L; Moreno Monteagudo, JA; Moreno Otero, R; Trapero Marugán, M | 1 |
| Desch, S; Klinker, H; Langmann, P; Lingenauber, C; Väth, T; Zilly, M | 1 |
| Gervais, A | 1 |
| Zoulim, F | 1 |
| Hilleret, MN; Leroy, V | 1 |
| Asselah, T | 1 |
| Avenhaus, W; Domschke, W; Menzel, J; Poremba, C; Ullerich, H | 1 |
| Dantzler, TE; Lawitz, EJ | 1 |
| Zeuzem, S | 1 |
| Kuzmic, P; Lake-Bakaar, G; Ruffini, L | 1 |
| Adinolfi, LE; Ruggiero, G; Tonziello, A; Utili, R | 1 |
| Beld, MG; Dijkgraaf, MG; Reesink, HW; Sentjens, RE; Weegink, CJ | 1 |
| Maygers, J; Pande, H; Thuluvath, PJ | 1 |
| Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Herrmann, E; Hinrichsen, H; Hopf, U; Kronenberger, B; Nasser, S; Pape, GR; Spengler, U; Wursthorn, K; Zeuzem, S | 2 |
| Arnold, R; Berg, T; Herrmann, E; Junge, U; Kullmann, F; Lafrenz, M; Musch, E; Pascu, M; Pausch, J; Ramadori, G; Teuber, G; Weidenbach, H; Wiedmann, KH; Zankel, M; Zeuzem, S | 1 |
| Rodés, J | 1 |
| Calleja, JL; Castillo, P; Erdozain, JC; Escartín, P; Olveira, A; Segura, JM; Serrano, C | 1 |
| Abergel, A; Bacq, Y; Blanchi, A; Causse, X; Fouchard-Hubert, I; Loustaud-Ratti, V; Lunel, F; Payan, C; Rifflet, H; Silvain, C; Veillon, P | 1 |
| Brillanti, S; Levantesi, F; Nigro, G; Roda, E; Vicari, S | 1 |
| Anania, FA; Black, M; Fairbanks, KD; Gelrud, LG; Lobis, IF; Maheshwari, A; Mehdi, J; Ryan, MJ; Thuluvath, PJ; Wu, LL | 1 |
| Engler, S; Flechtenmacher, C; Gugler, R; Kallinowski, B; Stremmel, W; Wiedemann, KH | 1 |
| Khokhar, N | 1 |
| Denk, DM; Ferenci, P; Formann, E; Gangl, A; Jessner, W; Munda-Steindl, P; Stauber, R; Zollner, G | 1 |
| Peters, T; Rasenack, J; Reincke, M; Schories, M | 1 |
| Basso, M; Delfino, A; Pelli, N; Picciotto, A; Rossol, S; Torre, F | 1 |
| Bolognini, S; Careddu, GF; Cottoni, F; Deplano, A; Garrucciu, G; Lissia, A; Manzoni, NE; Montesu, MA; Solinas, A; Tocco, A | 1 |
| de Knegt, RJ; Orlent, H; Schalm, SW; Veldt, BJ; Vrolijk, JM | 1 |
| Cholongitas, E; Papatheodoridis, GV | 1 |
| Artioli, S; Carosi, G; Maggiolo, F; Mignani, E; Paraninfo, G; Pastore, G; Puoti, M; Quinzan, GP; Raise, E; Ravasio, L; Resta, F; Rollo, A; Santantonio, T; Suter, F; Verucchi, G; Zaltron, S; Zanini, B | 1 |
| Canva, V; De Maeght, S; Deltenre, P; Dharancy, S; Henrion, J; Louvet, A; Mathurin, P; Paris, JC; Texier, F | 1 |
| Brillanti, S | 1 |
| Al-Ajmi, M; Al-Khaldi, J; Al-Nakib, B; Asker, H; Hasan, F; Owayed, S; Siddique, I; Varghese, R | 1 |
| Vogel, W | 1 |
| Datz, C; Hackl, F; Hegenbarth, K; Hofer, H; Jessner, W; Peter, F; Schütze, K; Stauber, RE; Steindl-Munda, P | 1 |
| Davis, GL | 1 |
| Altintas, E; Altiparmak, E; Cicek, B; Filik, L; Kilic, M; Odemis, B; Oguz, D; Zengin, N | 1 |
| Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Pradat, P; Trepo, C; Zoulim, F | 1 |
| Bernstein, DE; Brown, RS; Herrine, SK; Lentz, E; Ondovik, MS; Te, H | 1 |
| Andriulli, A; Annese, M; Bacca, D; Carretta, V; Cela, M; Conte, D; Festi, D; Guadagnino, V; Maio, G; Mangia, A; Minerva, N; Pazienza, V; Persico, M; Piattelli, M; Ricci, GL; Spirito, F | 1 |
| Barnes, DS; Bringman, D; Carey, WD; Farmer, D; Ferguson, R; Gramlich, T; Levinthal, G; Martin, LM; McCullough, AC; Mullen, KD; O'Shea, R; Ong, JP; Post, A; Tavill, AS; Younossi, ZM | 1 |
| Chemin, I; Guillaud, O; Khattab, E; Mrani, S; Trepo, C; Vieux, C; Vuillermoz, I; Zoulim, F | 1 |
| Amlie-Lefond, CM; Chusid, MJ; Ghanayem, NS; Hoffman, GM; Rupprecht, CE; Schwabe, MJ; Tieves, KS; Willoughby, RE | 1 |
| Attia, M; Badran, HM; Barakat, E; El-Nakeeb, A; El-Tawil, A; El-Zayadi, AR; Saied, A; Selim, O; Zalata, K | 1 |
| Romero Gómez, M | 1 |
| Sethi, A; Shiffman, ML | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J | 1 |
| Fediakina, IT; Glushkov, RG; Gus'kova, TA; Leneva, IA | 1 |
| Attia, M; Badran, HM; Barakat, EM; El-Nakeeb, A; El-Tawil, A; El-Zayadi, AR; Hamdy, H; Saied, A; Selim, O | 1 |
| Brunner, H; Datz, C; Ferenci, P; Formann, E; Gangl, A; Gschwantler, M; Hackl, F; Hubmann, R; Kessler, HH; Klingler, A; Laferl, H; Stauber, R; Steindl-Munda, P | 1 |
| Adeleine, P; Bailly, F; Maynard, M; Nemoz, C; Pradat, P; Rozier, F; Si Ahmed, SN; Trépo, C | 1 |
| Forestier, N; Friedrich-Rust, M; Zeuzem, S | 1 |
| Basso, M; Delfino, A; Pelli, N; Picciotto, A; Torre, F | 1 |
| Hoepffner, N; Nikodem, AB; Paul, KA; Teuber, G | 1 |
| Cornberg, M; Manns, MP; Wedemeyer, H | 1 |
| Borzio, M; Cargnel, A; Fargion, S; Maraschi, A | 1 |
| Andreoni, M; Anselmo, M; Basso, M; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Cusumano, S; Gallo, M; Garbagnoli, P; Giordanino, C; Grasso, A; Manca, A; Marenco, G; Percario, G; Picciotto, A; Rizzetto, M; Rizzi, R; Saracco, G; Sartori, M; Smedile, A; Tabone, M | 1 |
| Bonte, D; Capron, D; Castelain, S; Dedeurwaerder, S; Duverlie, G; François, C; Morel, V; Penin, F; Wychowski, C; Zawadzki, P | 1 |
| Hofmann, WP; Sarrazin, C; Wohnsland, A | 1 |
| Andrade, R; de la Mata, M; Diago, M; Granados, R; Muñoz de Rueda, P; Pérez, R; Romero, M; Ruiz-Extremera, A; Salmerón, J; Solá, R | 1 |
| Riley, TR; Taheri, MR | 1 |
| Ambühl, PM; Calanca, LN; Fehr, T; Fischer-Vetter, J; Jochum, W; Müllhaupt, B; Wüthrich, RP | 1 |
| Lynch, JP; Walsh, EE | 1 |
| Encke, J; Stremmel, W; Weigand, K | 1 |
| Andreone, P; Attard, L; Bernardi, M; Biselli, M; Boccia, S; Bonvicini, F; Cursaro, C; Furlini, G; Galli, S; Giacomoni, PL; Gramenzi, A; Lorenzini, S; Verucchi, G | 1 |
| Bischof, T; Gonvers, JJ; Mullhaupt, B; Renner, EL; Wenger, C | 1 |
| Chen, XY; Duan, X; Liu, GJ; Ni, J; Qiao, JQ; Wang, Q; Wei, J; Wu, TX; Zheng, J; Zhou, LK | 1 |
| Angelico, F; Angelico, M; Bandiera, F; Barlattani, A; Demelia, L; Forlini, G; Francioso, S; Gentile, S; Grieco, A; Guarascio, P; Koehler-Horst, B; Piccolo, P; Pilleri, G; Ponti, L; Rossi, Z; Soccorsi, F; Sorbello, O; Tarquini, P; Vecchia, RD; Zaru, S | 1 |
| Eason, J; Lipscomb, J; Nair, S | 1 |
| De Clercq, E; Kelly, JM; Kolocouris, N; Naesens, L; Prathalingam, SR; Tsotinis, A; Zoidis, G | 1 |
| Berg, T; Buggisch, P; Gerken, G; Goeser, T; Herrmann, E; Hinrichsen, H; Hofmann, WP; Manns, M; Spengler, U; Teuber, G; von Wagner, M; Weidenbach, H; Zeuzem, S | 1 |
| Fehér, J; Hagymási, K | 1 |
| David, D; Garcia, C; Guarda, DC; Rubin, J; Rupprecht, CE; Stamler, A; Willoughby, RE; Zohar, Z | 1 |
| Bailey, KW; Hurst, BL; Morrey, JD; Smee, DF; Wong, MH | 1 |
| Chrissafidou, A; Musch, E | 1 |
| Adler, M; Brenard, R; D'Heygere, F; Delwaide, J; Henrion, J; Horsmans, Y; Langlet, P; Lasser, L; Laureys, A; Michielsen, P; Mulkay, JP; Nevens, F; Van Vlierberghe, H | 1 |
| Driebe, EM; Engelthaler, DM; Hoopes, JD; Keim, PS; Le, MH; Nguyen, JT; Prichard, MN; Smee, DF; Spence, RP; Went, GT | 1 |
| Berg, T; Boland, GJ; de Vries, RA; Drenth, JP; Halangk, J; Kok, KF; van Herwaarden, AE; van Oijen, MG; van Soest, H | 1 |
| Chirino, RA; Chung, RT; Corey, KE; Dehesa-Violante, M; Gorospe, EC; Juarez, JA; Méndez-Navarro, J; Morán, S; Zheng, H | 1 |
| Boland, GJ; de Vries, RA; Drenth, JP; Houben, P; Koek, GH; Lieverse, RJ; Schipper, ME; Siersema, PD; van der Schaar, PJ; van der Sluys Veer, A; van Erpecum, KJ; van Hoek, B; van Ooteghem, NA; van Soest, H; Vrolijk, JM | 1 |
| Awad, T; Gluud, LL; Iorio, A; Marchesini, E | 1 |
| Burroughs, AK; Davidson, BR; Gurusamy, KS; Tsochatzis, E; Xirouchakis, E | 1 |
| Jackson, AC | 1 |
| Blair, PJ; de Jong, MD; Faix, DJ; Hoopes, JD; Le, MH; Nguyen, JT; Patick, AK; Prichard, MN; Smee, DF; Went, GT | 1 |
| Piccolo, P | 1 |
| Hung, T; Wan, Y; Wang, J; Yang, Y; Zhou, Z | 1 |
| Daruich, J | 1 |
| Razonable, RR | 1 |
| Choi, SH; Chon, GR; Han, MS; Hong, SB; Huh, JW; Kim, HR; Kim, MJ; Kim, SH; Kim, WY; Kim, YS; Ko, YG; Lee, KH; Ryu, YJ; Young Suh, G | 1 |
| Driebe, EM; Engelthaler, DM; Hoopes, JD; Keim, PS; Kelley, E; Nguyen, JT; Perelson, AS; Rong, L; Went, GT | 1 |
| Barnard, DL; de Jong, MD; Gross, M; Julander, JG; Nguyen, JT; Smee, DF; Went, GT | 1 |
| Abbas, Z; Hamid, S; Jafri, W; Raza, S | 1 |
| Beyler, AR; Coban, S; Dökmeci, A; Ekiz, F; Erdem, H; Köklü, S; Ormeci, N; Ozkan, H; Palabıyıkoğlu, M | 1 |
| Chen, J; Lin, Y; Shi, J; Xie, WF; Zeng, X | 1 |
| Cen, S; He, Z; Li, XY; Liu, ZL; Wang, X; Wang, Z; Wei, XL; Yin, X; Zhang, ZZ; Zhou, JM | 1 |
| Boeckh, MJ; de Jong, MD; Englund, JA; Lindegardh, N; Nguyen, JT; Pukrittayakamee, S; Renaud, C; Seo, S; Tambyah, PA; Tarning, J; Went, GT | 1 |
| Deng, L; Jiang, L; Wu, T | 1 |
| Diot, C; Jacob, Y; Munier, S; Naffakh, N; Rolland, T | 1 |
| Jang, HC; Jung, SI; Kang, SJ; Kee, SJ; Kwon, YS; Park, KH; Shin, JH | 1 |
| Khokhar, N; Niazi, TK; Qureshi, MO | 1 |
| Cui, F; He, Y; Liu, X; Yan, H; Yun, H; Zhang, Z | 1 |
| Awad, T; Brok, J; Gluud, C; Gluud, LL; Hauser, G; Mabrouk, M; Štimac, D; Thorlund, K | 1 |
| Broekman, M; Drenth, JP; Gluud, C; Lamers, MH | 2 |
| Deryabin, PG; Galegov, GA; Konstantinova, ID; L'vov, DK; Miroshnikov, AI; Muzyka, IS | 1 |
| Benschop, KS; Duizer, E; Koopmans, MP; van der Avoort, HG | 1 |
| Qian, M; Wang, W; Xiao, C; Xu, J; Yang, H; Zhang, Q | 1 |
| Ariza-Heredia, EJ; Chemaly, RF; Shahani, L | 1 |
| Bao, Y; Beasley, RL; Beeler, J; Beigel, JH; Bozzolo, DR; Dar, SM; Davey, RT; Holley, HP; Hoopes, J; Hughes, MD; Lane, HC; Losso, MH; Manosuthi, W; McClure, N; Myers, C; Panuto, J; Perez-Patrigeon, S; Slandzicki, A; Suwanpimolkul, G | 1 |
| Linjie, L; Lutao, X; Pin, L; Qunjie, P; Wang, D; Weijun, F | 1 |
77 review(s) available for amantadine and ribavirin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Virus infections.
Topics: Adrenal Cortex Hormones; Amantadine; Animals; Anti-Bacterial Agents; Bacterial Infections; Cytarabine; Deoxyglucose; gamma-Globulins; Humans; Idoxuridine; Immunotherapy; Interferon Inducers; Methisazone; Mice; Rabbits; Ribavirin; Vaccination; Viral Vaccines; Virus Diseases | 1976 |
Antivirals with clinical potential.
Topics: Amantadine; Animals; Antiviral Agents; Cytarabine; Herpes Labialis; Herpes Simplex; Humans; Idoxuridine; Influenza, Human; Inosine Pranobex; Interferon Inducers; Interferons; Keratitis, Dendritic; Levamisole; Methisazone; Ribavirin; Smallpox; Vidarabine | 1979 |
Antiviral agents: action and clinical use.
Topics: Amantadine; Antiviral Agents; Ascorbic Acid; Cytarabine; Humans; Idoxuridine; Influenza, Human; Inosine Pranobex; Interferons; Levamisole; Methisazone; Ribavirin; Vidarabine; Virus Replication | 1979 |
New trends in antiviral chemotherapy.
Topics: Amantadine; Animals; Antiviral Agents; Humans; Interferon Inducers; Interferons; Protein Biosynthesis; Purine Nucleosides; Pyrimidine Nucleosides; Reverse Transcriptase Inhibitors; Ribavirin; Structure-Activity Relationship | 1979 |
Therapeutic control of viral infections: chemotherapy, interferon and gamma globulin.
Topics: Amantadine; Animals; Benzimidazoles; Chickenpox; Cytarabine; gamma-Globulins; Hepatitis, Viral, Human; Herpes Simplex; Herpes Zoster; Humans; Idoxuridine; Inosine Pranobex; Interferons; Measles; Mumps; Phosphonoacetic Acid; Ribavirin; Rifampin; Rubella; Vaccination; Vaccinia virus; Vidarabine; Virus Diseases | 1979 |
Chemotherapy of virus diseases.
Topics: Amantadine; Antiviral Agents; Cytarabine; Drug Evaluation; Herpesviridae Infections; Humans; Idoxuridine; Interferon Inducers; Interferons; Polynucleotides; Respiratory Tract Infections; Ribavirin; Thiosemicarbazones; Vidarabine; Virus Cultivation; Virus Diseases | 1976 |
Inhibitors of influenza virus replication.
Topics: Amanitins; Amantadine; Animals; Camptothecin; Dactinomycin; Drug Evaluation; Humans; Influenza A virus; Ribavirin; RNA, Viral; Virus Replication | 1979 |
[Present state of antiviral therapy (author's transl)].
Topics: Amantadine; Antiviral Agents; Child; Cytarabine; Encephalitis; Herpes Simplex; Humans; Idoxuridine; Influenza, Human; Interferons; Keratitis, Dendritic; Osteosarcoma; Ribavirin; Smallpox; Thiosemicarbazones; Vidarabine | 1979 |
Antiviral chemotherapy and its significance to the poultry industry.
Topics: Amantadine; Animals; Antiviral Agents; Chickens; Cricetinae; Cytarabine; Herpesviridae; Humans; Idoxuridine; Keratitis, Dendritic; Marek Disease; Methisazone; Newcastle disease virus; Orthomyxoviridae; Poultry Diseases; Rabbits; Ribavirin; Thiosemicarbazones; Virus Diseases | 1975 |
Specific inhibitors of influenza virus replication as potential chemoprophylactic agents.
Topics: Adamantane; Amantadine; Animals; Antiviral Agents; DNA-Directed RNA Polymerases; Drug Resistance, Microbial; Humans; Influenza, Human; Models, Molecular; Orthomyxoviridae; Ribavirin; Virus Replication | 1975 |
Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections.
Topics: Adult; Amantadine; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Interferons; Middle Aged; Picornaviridae Infections; Respiratory Tract Infections; Respirovirus Infections; Rhinovirus; Ribavirin; Rimantadine; Virus Diseases | 1985 |
Chemotherapy of respiratory viruses.
Topics: Acyclovir; Adult; Amantadine; Animals; Antiviral Agents; Benzimidazoles; Child; Clinical Trials as Topic; Female; Humans; Influenza, Human; Interferons; Oximes; Pneumonia, Viral; Respiratory Tract Infections; Ribavirin; Rimantadine; Sulfonamides; Vidarabine; Virus Diseases | 1986 |
Respiratory pharmacology. Antiviral agents.
Topics: Acyclovir; Amantadine; Antiviral Agents; Ganciclovir; Herpesviridae Infections; Humans; Influenza, Human; Interferons; Ribavirin; Rimantadine; Vidarabine | 1986 |
Antiviral chemotherapy and prophylaxis of viral respiratory disease.
Topics: Amantadine; Animals; Antiviral Agents; Humans; Interferons; Respiratory Tract Infections; Ribavirin; Virus Diseases | 1987 |
Antiviral agents for respiratory infections.
Topics: Amantadine; Antiviral Agents; Child; Humans; Interferons; Respiratory Tract Infections; Ribavirin; Rimantadine; Virus Diseases | 1988 |
Antiviral agents.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Amantadine; Antiviral Agents; Ganciclovir; Humans; Ribavirin; Vidarabine; Virus Diseases | 1988 |
Clinical considerations in the diagnosis of viral respiratory infections.
Topics: Amantadine; Antibodies, Monoclonal; Antigens, Viral; Cross Infection; Humans; Influenza A virus; Influenza, Human; Respiratory Syncytial Viruses; Respiratory Tract Infections; Respirovirus Infections; Ribavirin; Risk; Virus Diseases | 1986 |
Antiviral chemotherapy.
Topics: Acyclovir; Amantadine; Antiviral Agents; DNA Viruses; Humans; Infant; Infant, Newborn; Ribavirin; RNA Viruses; Vidarabine; Virus Diseases | 1986 |
What's new in the treatment of viral respiratory infections in children. Part II.
Topics: Amantadine; Child; Child, Preschool; Humans; Infant; Respiratory Tract Infections; Ribavirin; Ribonucleosides; Virus Diseases | 1985 |
Influenza--recent developments in prophylaxis and treatment.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Administration, Oral; Aerosols; Amantadine; Humans; Influenza, Human; Interferon Type I; Phosphatidylethanolamines; Ribavirin; Rimantadine | 1985 |
Antiviral therapy. Respiratory infections, genital herpes, and herpetic keratitis.
Topics: Acyclovir; Adult; Amantadine; Antiviral Agents; Child; Female; Herpes Genitalis; Humans; Idoxuridine; Infant; Infant, Newborn; Influenza, Human; Keratitis, Dendritic; Male; Picornaviridae Infections; Recurrence; Respiratory Syncytial Viruses; Respiratory Tract Infections; Respirovirus Infections; Rhinovirus; Ribavirin; Rimantadine; Trifluridine; Vidarabine | 1984 |
Antiviral activity of amantadine: a review of laboratory and clinical data.
Topics: Amantadine; Animals; Antiviral Agents; Culture Techniques; Drug Resistance, Microbial; Hemagglutinins; Humans; Influenza Vaccines; Interferons; Orthomyxoviridae; Peptides; Recurrence; Ribavirin; Vaccination; Virus Replication | 1980 |
Antiviral drugs 1983.
Topics: Acyclovir; Amantadine; Antiviral Agents; Clinical Trials as Topic; Female; Herpes Genitalis; Herpes Simplex; Humans; Idoxuridine; Influenza, Human; Interferons; Keratitis, Dendritic; Male; Ribavirin; Rimantadine; Trifluridine; Vidarabine | 1983 |
Antiviral chemotherapy.
Topics: Acyclovir; Amantadine; Animals; Antiviral Agents; Bromodeoxyuridine; Female; Hepatitis B; Herpes Genitalis; Herpes Simplex; Herpes Zoster; Humans; Idoxuridine; In Vitro Techniques; Interferons; Male; Neoplasms; Papillomaviridae; Respiratory Tract Infections; Ribavirin; Rimantadine; Tumor Virus Infections; Vidarabine | 1984 |
[Future of antifungal and antiviral agents. 2. Antiviral agents. b. Present status of chemotherapy of viral infections of the respiratory tract].
Topics: Amantadine; Antiviral Agents; Humans; Interferons; Respiratory Tract Infections; Ribavirin; Rimantadine; Virus Diseases | 1984 |
Properties of antiviral agents. 2.
Topics: Amantadine; Antiviral Agents; DNA Viruses; Female; Humans; Interferons; Ribavirin; Rimantadine; RNA Viruses; Virus Diseases | 1984 |
Antiviral agents.
Topics: Acyclovir; Amantadine; Animals; Antiviral Agents; Herpes Simplex; Herpes Zoster; Humans; Idoxuridine; Influenza A virus; Keratitis, Dendritic; Methisazone; Ribavirin; Smallpox; Vidarabine; Virus Diseases | 1983 |
Adverse effects and drug interactions of clinical importance with antiviral drugs.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Interactions; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Vidarabine; Zalcitabine; Zidovudine | 1994 |
Anti-infective therapy for viral pneumonia.
Topics: Acyclovir; Amantadine; Antiviral Agents; Foscarnet; Ganciclovir; Humans; Neuraminidase; Pneumonia, Viral; Ribavirin; Rimantadine | 1995 |
[Drugs active against respiratory viruses].
Topics: Amantadine; Antiviral Agents; Orthomyxoviridae; Respiratory Syncytial Viruses; Respiratory Tract Infections; Rhinovirus; Ribavirin; Viruses | 1997 |
Antivirals for pandemic influenza.
Topics: Amantadine; Antiviral Agents; Humans; Influenza, Human; Neuraminidase; Ribavirin; Rimantadine | 1997 |
[Therapy of chronic hepatitis C: facing a breakthrough?].
Topics: Amantadine; Clinical Trials as Topic; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 1998 |
Antiviral drugs in healthy children.
Topics: Acyclovir; Amantadine; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration Schedule; Herpes Simplex; Humans; Respiratory Syncytial Virus Infections; Ribavirin; Rimantadine; Virus Diseases | 1998 |
[Chronic hepatitis C--therapeutic modalities for interferon failure].
Topics: Amantadine; Antiviral Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure | 1998 |
Underused options for preventing and treating influenza.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Child; Child, Preschool; Drug Administration Routes; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Orthomyxoviridae; Pyrans; Ribavirin; Rimantadine; Sialic Acids; Zanamivir | 1999 |
[Prophylaxis and treatment of respiratory infections caused by influenza virus types A and B].
Topics: Amantadine; Antiviral Agents; Drug Resistance, Microbial; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Ribavirin; Rimantadine | 1999 |
Antiviral agents for non-human immunodeficiency virus infections.
Topics: 2-Aminopurine; Acetamides; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Microbial; Drugs, Investigational; Enzyme Inhibitors; Famciclovir; Foscarnet; Ganciclovir; Guanidines; Guanine; Humans; Interferons; Lamivudine; Neuraminidase; Organophosphonates; Organophosphorus Compounds; Oseltamivir; Pyrans; Ribavirin; Sialic Acids; Valacyclovir; Valine; Virus Diseases; Zanamivir | 1999 |
New treatment strategies in non-responder patients with chronic hepatitis C.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure | 1999 |
Prevention and treatment of influenza in immunocompromised patients.
Topics: Aerosols; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Bone Marrow Transplantation; Drug Resistance, Microbial; Humans; Immunocompromised Host; Influenza Vaccines; Influenza, Human; Infusions, Intravenous; Organ Transplantation; Orthomyxoviridae; Primary Prevention; Ribavirin; Rimantadine | 1997 |
Drug-resistant viral hepatitis.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Microbial; Hepacivirus; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Ribavirin | 2000 |
[Treatments for hepatitis virus C infections].
Topics: Amantadine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Prognosis; Ribavirin | 2001 |
Management of interferon therapy nonresponders.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Ribavirin; RNA, Viral; Ursodeoxycholic Acid | 2001 |
New therapies for the treatment of chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligonucleotides, Antisense; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Catalytic | 2002 |
[Treatment of chronic hepatitis C in patients not responding to interferon].
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure | 2000 |
[Antiviral treatment of chronic hepatitis C in interferon nonresponders].
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure | 2002 |
[Chronic hepatitis C in HIV-HCV coinfected patients].
Topics: Adult; Age Factors; Amantadine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Child; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Meta-Analysis as Topic; Pilot Projects; Prevalence; Ribavirin; Risk Factors | 2002 |
[Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment].
Topics: Amantadine; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Transaminases; Treatment Failure; Viral Load | 2002 |
[Evaluation of response to treatment in chronic hepatitis C].
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Liver Neoplasms; Meta-Analysis as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Transaminases; Viremia | 2002 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Mental Disorders; Middle Aged; Monitoring, Physiologic; Quality of Life; Recurrence; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors | 2002 |
[Chronic hepatitis C: what to do if the first treatment failed?].
Topics: Amantadine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Ethanol; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Mice; Mice, Transgenic; Multicenter Studies as Topic; Obesity; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; Smoking; Time Factors | 2002 |
Treatment of chronic hepatitis C in nonresponders to previous therapy.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
[Combination therapy for chronic viral hepatitis C].
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
The treatment of hepatitis C: history, presence and future.
Topics: Amantadine; Antiviral Agents; Chronic Disease; Consensus; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Ribavirin | 2004 |
Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Recurrence; Ribavirin | 2004 |
Evaluation of amantadine in chronic hepatitis C: a meta-analysis.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2004 |
Role of amantadine and other adjuvant therapies in the treatment of hepatitis C.
Topics: Adjuvants, Immunologic; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2004 |
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
Topics: Adjuvants, Immunologic; Alcoholism; Amantadine; Antiviral Agents; Black or African American; Clinical Trials as Topic; Counseling; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferons; Liver Cirrhosis; Meta-Analysis as Topic; Oligonucleotides, Antisense; Patient Compliance; Ribavirin; RNA, Viral; Thymalfasin; Thymosin; Time Factors; White People | 2004 |
Treatment of acute and chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Recurrence; Ribavirin | 1997 |
Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response.
Topics: Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Life Style; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Refusal; Viral Load | 2005 |
[Current treatment of hepatitis C virus infection].
Topics: Acute Disease; Amantadine; Animals; Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Transaminases; Treatment Failure; Viral Envelope Proteins; Viral Hepatitis Vaccines | 2005 |
[High dose repeat therapy in previously treated patients with chronic hepatitis C].
Topics: Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2006 |
Treating viral hepatitis C: efficacy, side effects, and complications.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome | 2006 |
Viral determinants of resistance to treatment in patients with hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2007 |
Influenza: evolving strategies in treatment and prevention.
Topics: Aged; Amantadine; Antiviral Agents; Centers for Disease Control and Prevention, U.S.; Child, Preschool; Humans; Infant; Influenza A virus; Influenza B virus; Influenza Vaccines; Influenza, Human; Oseltamivir; Practice Guidelines as Topic; Ribavirin; Rimantadine; United States; Zanamivir | 2007 |
Treatment of hepatitis C virus infection.
Topics: Acute Disease; Amantadine; Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Chinese medicinal herbs for influenza.
Topics: Amantadine; Antiviral Agents; Drugs, Chinese Herbal; Humans; Influenza, Human; Phytotherapy; Randomized Controlled Trials as Topic; Ribavirin | 2007 |
Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2010 |
Antiviral therapy for recurrent liver graft infection with hepatitis C virus.
Topics: Amantadine; Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Randomized Controlled Trials as Topic; Recurrence; Ribavirin | 2010 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2012 |
Chinese medicinal herbs for influenza.
Topics: Amantadine; Antiviral Agents; Drugs, Chinese Herbal; Humans; Influenza, Human; Phytotherapy; Randomized Controlled Trials as Topic; Ribavirin | 2013 |
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2014 |
Aminoadamantanes for chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Mycophenolic Acid; Randomized Controlled Trials as Topic; Ribavirin | 2014 |
Antivirals against enteroviruses: a critical review from a public-health perspective.
Topics: Amantadine; Antiviral Agents; Child; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; Enterovirus; Enterovirus Infections; Epidemiological Monitoring; Hepatitis C; Humans; Immunocompromised Host; Influenza, Human; Public Health; Ribavirin | 2015 |
Antiviral therapy for respiratory viral infections in immunocompromised patients.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Coronavirus Infections; Cyclopentanes; Guanidines; Humans; Immunocompromised Host; Influenza, Human; Oseltamivir; Palivizumab; Paramyxoviridae Infections; Picornaviridae Infections; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin; Zanamivir | 2017 |
57 trial(s) available for amantadine and ribavirin
| Article | Year |
|---|---|
Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A.
Topics: Adult; Amantadine; Antibodies, Viral; Bilirubin; Body Temperature; Clinical Trials as Topic; Humans; Influenza A virus; Influenza, Human; Male; Orthomyxoviridae; Placebos; Ribavirin; Ribonucleosides | 1976 |
Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections.
Topics: Adult; Amantadine; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Interferons; Middle Aged; Picornaviridae Infections; Respiratory Tract Infections; Respirovirus Infections; Rhinovirus; Ribavirin; Rimantadine; Virus Diseases | 1985 |
Chemotherapy of respiratory viruses.
Topics: Acyclovir; Adult; Amantadine; Animals; Antiviral Agents; Benzimidazoles; Child; Clinical Trials as Topic; Female; Humans; Influenza, Human; Interferons; Oximes; Pneumonia, Viral; Respiratory Tract Infections; Ribavirin; Rimantadine; Sulfonamides; Vidarabine; Virus Diseases | 1986 |
Antiviral chemotherapy and chemoprophylaxis.
Topics: Acyclovir; Adult; Aged; Amantadine; Antiviral Agents; Chickenpox; Clinical Trials as Topic; Cytomegalovirus; Encephalitis; Foscarnet; Guanosine Triphosphate; Herpes Simplex; Herpes Zoster; Herpesviridae Infections; Humans; Infant, Newborn; Infant, Newborn, Diseases; Influenza A virus; Influenza, Human; Phosphonoacetic Acid; Respiratory Tract Infections; Ribavirin; Rimantadine; Vidarabine; Virus Diseases | 1985 |
Ribavirin small-particle aerosol treatment of influenza.
Topics: Administration, Oral; Adult; Aerosols; Amantadine; Clinical Trials as Topic; Disease Outbreaks; Humans; Influenza, Human; Particle Size; Random Allocation; Respiratory Therapy; Ribavirin; Ribonucleosides | 1981 |
Antiviral drugs 1983.
Topics: Acyclovir; Amantadine; Antiviral Agents; Clinical Trials as Topic; Female; Herpes Genitalis; Herpes Simplex; Humans; Idoxuridine; Influenza, Human; Interferons; Keratitis, Dendritic; Male; Ribavirin; Rimantadine; Trifluridine; Vidarabine | 1983 |
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral; Statistics, Nonparametric | 1999 |
Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Amantadine; Clinical Enzyme Tests; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral | 2000 |
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Prospective Studies; Ribavirin; RNA, Viral | 2000 |
HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2000 |
A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin; Thyrotropin | 2001 |
Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 2001 |
Clearance kinetics of hepatitis C virus under different antiviral therapies.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors | 2001 |
Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine.
Topics: Adult; Amantadine; Antiviral Agents; Drug Synergism; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Sarcoidosis | 2002 |
High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.
Topics: Adult; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2002 |
Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Pilot Projects; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Failure | 2003 |
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
Topics: Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Placebos; Recombinant Proteins; Ribavirin | 2003 |
Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
[Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)].
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin | 2003 |
Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
Topics: Adult; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2003 |
Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2004 |
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Transaminases | 2004 |
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
Topics: Adult; Amantadine; Audiometry; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Sampling Studies; Severity of Illness Index | 2004 |
[Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha].
Topics: Amantadine; Antiviral Agents; Autoantibodies; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Islets of Langerhans; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Treatment Failure | 2004 |
Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon?
Topics: Adult; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Solvents; Treatment Outcome | 2004 |
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure | 2004 |
Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Austria; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Secondary Prevention; Treatment Failure; Treatment Outcome | 2004 |
Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).
Topics: Adult; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Survival Analysis | 2005 |
Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome; Viral Load | 2005 |
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Amantadine; Biopsy, Needle; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Probability; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Single-Blind Method; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2005 |
Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia | 2005 |
Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Necrosis; Protective Agents; Ribavirin; RNA, Viral; Silymarin; Treatment Outcome; Ursodeoxycholic Acid | 2005 |
Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
Topics: Adult; Amantadine; Antiviral Agents; Drug Carriers; Drug Combinations; Drug Costs; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2005 |
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Topics: Adult; Amantadine; Antiviral Agents; Disease Progression; Double-Blind Method; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).
Topics: Adult; Aged; Amantadine; Antiviral Agents; Biopsy; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Triple antiviral therapy in HCV positive patients who failed prior combination therapy.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin | 2006 |
A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.
Topics: Adult; Aged; Amantadine; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Proteins | 2007 |
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2007 |
Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.
Topics: Adult; Amantadine; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Prospective Studies; Ribavirin | 2007 |
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin | 2007 |
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Psychometrics; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study.
Topics: Adolescent; Adult; Aged; Amantadine; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2007 |
Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponde
Topics: Adult; Age Factors; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Young Adult | 2008 |
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Topics: Amantadine; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Patient Selection; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome; Young Adult | 2009 |
A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
Topics: Adult; Amantadine; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Logistic Models; Male; Mexico; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
No beneficial effects of amantadine in treatment of chronic hepatitis C patients.
Topics: Adult; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2012 |
Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.
Topics: Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Turkey; Viral Load | 2012 |
Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.
Topics: Adult; Amantadine; Drug Resistance, Viral; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Influenza A virus; Influenza, Human; Male; Mutation; Oseltamivir; Pilot Projects; Ribavirin; Viral Load; Young Adult | 2013 |
Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
Topics: Amantadine; Antiviral Agents; Argentina; Australia; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Mexico; Oseltamivir; Ribavirin; Thailand; United States | 2017 |
134 other study(ies) available for amantadine and ribavirin
| Article | Year |
|---|---|
Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Drug Screening Assays, Antitumor; HeLa Cells; HIV-1; HIV-2; Humans; Imidazoles; Influenza A virus; Parainfluenza Virus 3, Human; Respiratory Syncytial Viruses; RNA Viruses; Structure-Activity Relationship; Triazines; Vero Cells | 1995 |
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
Topics: Adamantane; Animals; Antiviral Agents; Cell Division; Cell Line; Cell Survival; Chlorocebus aethiops; Cytopathogenic Effect, Viral; Dogs; Humans; Spiro Compounds | 1994 |
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
Topics: Adamantane; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Cytomegalovirus; Dogs; Enterovirus B, Human; Herpesvirus 3, Human; HIV-1; HIV-2; Humans; Indicators and Reagents; Microbial Sensitivity Tests; Molecular Structure; Orthomyxoviridae; Reoviridae; Semliki forest virus; Sindbis Virus; Structure-Activity Relationship; Vaccinia virus; Vesicular stomatitis Indiana virus | 1996 |
Two new naphthoquinones with antiviral activity from Rhinacanthus nasutus.
Topics: Antiviral Agents; Chemical Fractionation; Cytomegalovirus; Humans; Lethal Dose 50; Magnetic Resonance Spectroscopy; Mass Spectrometry; Naphthoquinones; Plant Extracts; Plants, Medicinal | 1996 |
Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus.
Topics: Antineoplastic Agents, Phytogenic; Antiviral Agents; Drug Screening Assays, Antitumor; Influenza A virus; Lignans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Plant Leaves; Plants, Medicinal; Spectrophotometry, Ultraviolet; Thailand; Viral Plaque Assay | 1997 |
Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Influenza A virus; Magnetic Resonance Spectroscopy; Models, Molecular; Piperidines | 1999 |
Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups.
Topics: Amantadine; Amines; Antiviral Agents; Influenza A virus; Microbial Sensitivity Tests; Molecular Conformation; Pyrrolidines | 2001 |
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
Topics: Adamantane; Antiviral Agents; Cell Line; Humans; Influenza A virus; Influenza, Human; Models, Molecular; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Pyrrolidines; Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Design and synthesis of bioactive adamantane spiro heterocycles.
Topics: Adamantane; Animals; Antiprotozoal Agents; Antiviral Agents; Heterocyclic Compounds; Influenza A virus; Leishmania; Trypanosoma | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
Topics: Animals; Antiviral Agents; Aza Compounds; Catalysis; Cell Line; DNA Viruses; Drug Resistance, Viral; Humans; Hydrogenation; Nucleosides; Palladium; Pyrimidine Nucleosides; RNA Viruses; Structure-Activity Relationship; Sulfanilamide; Sulfanilamides | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
Topics: Adamantane; Animals; Antiviral Agents; Dogs; Humans; Influenza A Virus, H3N2 Subtype; Magnetic Resonance Spectroscopy; Molecular Structure; Piperidines; Rimantadine; Structure-Activity Relationship | 2009 |
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
Topics: Amino Acids; Animals; Anti-HIV Agents; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Drug Resistance, Viral; Enterovirus B, Human; HIV Reverse Transcriptase; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Lymphocytes; Mice; Models, Molecular; Molecular Conformation; Mutation; Protein Binding; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Sulfones; Virus Replication | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
Topics: Anti-Bacterial Agents; Antiviral Agents; Diazonium Compounds; Doxorubicin; Gram-Positive Bacteria; Microbial Sensitivity Tests; Orthomyxoviridae; Teicoplanin | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
Topics: Anti-Bacterial Agents; Antiviral Agents; Catalysis; Copper; Doxorubicin; Humans; Influenza A Virus, H1N1 Subtype; Microbial Sensitivity Tests; Ristocetin | 2010 |
Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
Topics: Antiviral Agents; Cell Line; Drug Evaluation, Preclinical; Humans; Magnetic Resonance Spectroscopy; Quinazolines; Schiff Bases; Spectrophotometry, Infrared | 2010 |
Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
Topics: Adamantane; Alcohols; Amines; Animals; Antiviral Agents; Drug Design; Influenza A virus; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Spectrophotometry, Infrared; Trypanosoma brucei brucei | 2010 |
4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
Topics: Animals; Anti-Infective Agents; Benzenesulfonates; Cell Survival; Cells, Cultured; Chlorocebus aethiops; Dogs; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; HeLa Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Quantitative Structure-Activity Relationship; Stereoisomerism; Structure-Activity Relationship; Vero Cells; Viruses | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
Topics: Aminoquinolines; Animals; Antimalarials; Cell Line; DNA; Dogs; Heme; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Plasmodium falciparum; Protoporphyrins; Pyrimidines; Structure-Activity Relationship; Viruses | 2012 |
Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
Topics: Anti-Bacterial Agents; Antiviral Agents; Cell Line; Cell Survival; Drug Resistance, Viral; Gram-Positive Bacteria; Herpesvirus 1, Human; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Isoindoles; Microbial Sensitivity Tests; o-Phthalaldehyde; Teicoplanin | 2012 |
Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
Topics: Adamantane; Amides; Animals; Antiviral Agents; Aza Compounds; Chickens; Dogs; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Madin Darby Canine Kidney Cells; Microwaves; Orthomyxoviridae; Spiro Compounds; Structure-Activity Relationship; Virus Replication | 2012 |
Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
Topics: Anti-Bacterial Agents; Antiviral Agents; Dose-Response Relationship, Drug; Doxorubicin; Fluorescence; Gram-Positive Bacteria; Microbial Sensitivity Tests; Molecular Conformation; Orthomyxoviridae; Structure-Activity Relationship | 2012 |
Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
Topics: Antimalarials; Antiviral Agents; Cell Line; Chemistry Techniques, Synthetic; DNA; Heme; Humans; Plasmodium falciparum; Pyrimidines; Structure-Activity Relationship | 2013 |
Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
Topics: Animals; Antiviral Agents; Cells, Cultured; Chlorocebus aethiops; Dogs; Dose-Response Relationship, Drug; HeLa Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Pyrimidinones; Stereoisomerism; Structure-Activity Relationship; Vero Cells; Viruses | 2013 |
3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
Topics: Amantadine; Animals; Antiviral Agents; Aza Compounds; Bridged-Ring Compounds; Dogs; Drug Design; Drug Resistance, Viral; Guanidines; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Mutation; Pyrrolidines; Structure-Activity Relationship; Viral Matrix Proteins | 2013 |
Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
Topics: | 2012 |
Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
Topics: Animals; Antiviral Agents; Binding Sites; Dogs; Dose-Response Relationship, Drug; Lipid Bilayers; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Molecular Structure; Orthomyxoviridae; Structure-Activity Relationship; Teicoplanin | 2014 |
Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
Topics: Alkaloids; Animals; Antiviral Agents; Cell Line, Tumor; Cell Survival; Cytopathogenic Effect, Viral; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Viral; Eurotium; HEK293 Cells; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Molecular Structure; Piperazines; Structure-Activity Relationship; Viral Plaque Assay | 2015 |
A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
Topics: Anti-Bacterial Agents; Antiviral Agents; Chemistry Techniques, Synthetic; Circular Dichroism; Computer Simulation; Magnetic Resonance Spectroscopy; Orthomyxoviridae; Protein Conformation; Ristocetin; Structure-Activity Relationship; Teicoplanin | 2015 |
Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
Topics: Animals; Antiviral Agents; Aquatic Organisms; Benzofurans; Dogs; Dose-Response Relationship, Drug; Influenza A virus; Lactones; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Onygenales; Structure-Activity Relationship | 2016 |
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
Topics: Animals; Antiviral Agents; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; HIV-1; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Uracil | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
Topics: Antiviral Agents; Crystallography, X-Ray; Dose-Response Relationship, Drug; Folic Acid Antagonists; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Proguanil; Respiratory Syncytial Viruses; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Triazines | 2017 |
Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
Topics: Aniline Compounds; Binding Sites; HeLa Cells; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Protein Conformation; Virus Internalization | 2018 |
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
Topics: Antiviral Agents; Cell Line; DNA Viruses; Drug Stability; Humans; Nucleosides; Organophosphonates; Prodrugs; RNA Viruses; Structure-Activity Relationship | 2018 |
Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
Topics: Antiviral Agents; Aza Compounds; Dose-Response Relationship, Drug; Folic Acid Antagonists; Models, Molecular; Molecular Structure; Orthomyxoviridae; Spiro Compounds; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Triazines | 2018 |
Synthesis and
Topics: | 2017 |
Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
Topics: Antiviral Agents; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Influenza A virus; Influenza B virus; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Teicoplanin | 2018 |
Synthesis of d-(+)-camphor-based
Topics: | 2018 |
DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses.
Topics: | 2019 |
Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Ascorbic Acid; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Triazoles; Viruses | 2019 |
Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
Topics: Camphor; Ethanolamines; Humans; Influenza, Human; Structure-Activity Relationship | 2019 |
Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
Topics: Animals; Antiviral Agents; Dogs; Dose-Response Relationship, Drug; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Hydrogen-Ion Concentration; Indoles; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Protein Refolding; Spiro Compounds; Structure-Activity Relationship; Thiazolidines | 2020 |
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
Topics: | 2013 |
Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.
Topics: Acetophenones; Adsorption; Animals; Antiviral Agents; Dogs; Drug Discovery; Drug Resistance, Viral; Female; Hemagglutinin Glycoproteins, Influenza Virus; Influenza A virus; Madin Darby Canine Kidney Cells; Membrane Fusion; Mice; Tissue Distribution; Virus Internalization; Virus Replication | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Current state of antiviral chemotherapy (author's transl)].
Topics: Amantadine; Antiviral Agents; Humans; Idoxuridine; Interferons; Methisazone; Ribavirin; Vidarabine | 1979 |
The use of ferret trachea organ cultures for therapeutic studies of anti-influenzal drugs. II. Comparison of four compounds in tissue culture and in organ culture.
Topics: Amantadine; Amines; Animals; Antiviral Agents; Carnivora; Culture Techniques; Cycloparaffins; Drug Resistance, Microbial; Ferrets; Haplorhini; Influenza A virus; Models, Biological; Organ Culture Techniques; Ribavirin; Time Factors; Trachea | 1978 |
The relative potencies of anti-influenza compounds.
Topics: Adamantane; Amantadine; Amines; Animals; Antiviral Agents; Cells, Cultured; Cycloparaffins; Influenza A virus; Mice; Microbial Sensitivity Tests; Orthomyxoviridae Infections; Ribavirin | 1977 |
Activity of amantadine, rimantadine, and ribavirin against swine influenza in mice and squirrel monkeys.
Topics: Amantadine; Animals; Female; Haplorhini; Influenza A virus; Male; Mice; Orthomyxoviridae Infections; Ribavirin; Ribonucleosides; Saimiri; Time Factors | 1978 |
Antiviral agents.
Topics: Amantadine; Antiviral Agents; Humans; Idoxuridine; Influenza, Human; Methisazone; Ribavirin; Vidarabine | 1977 |
Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice.
Topics: Administration, Intranasal; Aerosols; Amantadine; Animals; Antiviral Agents; Female; Injections, Intraperitoneal; Mice; Mice, Inbred Strains; Orthomyxoviridae Infections; Pneumonia, Viral; Ribavirin | 1976 |
Antiviral agents in influenza--summary of Influenza Workshop VIII.
Topics: Amantadine; Animals; Antiviral Agents; Drug Evaluation; Humans; Influenza, Human; Interferon Inducers; Interferons; Neuraminidase; Pneumonia; Pneumonia, Viral; Ribavirin; Terpenes; Vaccination; Viral Interference | 1976 |
Approaches to antiviral chemotherapy: a status report.
Topics: Amantadine; Animals; Antiviral Agents; Cytarabine; Drug Evaluation; Drug Evaluation, Preclinical; Formycins; Humans; Idoxuridine; Methisazone; Ribavirin; Vidarabine; Virus Diseases | 1976 |
A comparison of test methods in influenza chemotherapy.
Topics: Allantois; Amantadine; Animals; Cells, Cultured; Chick Embryo; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Ribavirin; Ribonucleosides | 1975 |
Antivirals for the chemoprophylaxis and treatment of influenza.
Topics: Administration, Intranasal; Administration, Oral; Amantadine; Drug Resistance; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Ribavirin; Rimantadine | 1992 |
Antiviral therapy. New drugs and their uses.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Amantadine; Antiviral Agents; Chickenpox; Common Cold; Cytomegalovirus Infections; Herpes Simplex; Herpes Zoster; Herpesviridae Infections; Herpesvirus 4, Human; Humans; Influenza, Human; Interferons; Ribavirin; Rimantadine; Thymidine; Vidarabine; Virus Diseases; Zidovudine | 1986 |
New modalities in antiviral therapy.
Topics: Acyclovir; Amantadine; Antiviral Agents; Common Cold; Herpesviridae Infections; Humans; Interferons; Respiratory Tract Infections; Respirovirus Infections; Ribavirin; Virus Diseases | 1986 |
Antiviral drugs for common respiratory diseases. What's here, what's to come.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Child; Female; Humans; Infant; Infant, Newborn; Influenza, Human; Interferons; Paramyxoviridae Infections; Pneumonia, Viral; Pregnancy; Respiratory Syncytial Viruses; Respiratory Tract Infections; Respirovirus Infections; Ribavirin; Rimantadine; Virus Diseases | 1988 |
[A new inhalation apparatus and its application to screening of anti-influenza agents].
Topics: Aerosols; Amantadine; Animals; Antiviral Agents; Drug Evaluation, Preclinical; Female; Mice; Orthomyxoviridae Infections; Plant Extracts; Ribavirin | 1986 |
Influence of twenty potentially antiviral substances on in vitro multiplication of hepatitis A virus.
Topics: Amantadine; Antiviral Agents; Cell Line; Cytarabine; Drug Evaluation, Preclinical; Hepatitis A; Hepatovirus; Humans; Radioimmunoassay; Ribavirin; Virus Replication | 1986 |
Favorable outcome after treatment with amantadine and ribavirin in a pregnancy complicated by influenza pneumonia. A case report.
Topics: Adult; Amantadine; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Influenza A virus; Influenza, Human; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ribavirin; Ribonucleosides | 1988 |
Antiviral agents.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Amantadine; Antiviral Agents; Ganciclovir; Herpes Simplex; Humans; Idoxuridine; Influenza A virus; Influenza, Human; Ribavirin; Rimantadine; Thymidine; Vidarabine; Viruses; Zidovudine | 1987 |
Combinations of antiviral agents for treatment of influenza virus infections.
Topics: Amantadine; Animals; Antiviral Agents; Drug Synergism; Drug Therapy, Combination; In Vitro Techniques; Orthomyxoviridae Infections; Ribavirin; Rimantadine | 1986 |
Activity of selenazofurin against influenza A and B viruses in vitro.
Topics: Amantadine; Animals; Cell Division; Cells, Cultured; Cytopathogenic Effect, Viral; Dogs; In Vitro Techniques; Influenza A virus; Influenza B virus; Organoselenium Compounds; Ribavirin; Ribonucleosides; Selenium; Virus Replication | 1985 |
Evaluation of antiviral substances against influenza A virus strains by the haemadsorption reduction test.
Topics: Amantadine; Antiviral Agents; Deoxyglucose; Drug Evaluation, Preclinical; Hemadsorption Inhibition Tests; Influenza A virus; Microbiological Techniques; Ribavirin; Rimantadine | 1980 |
Increasing experience for the evaluation of antiviral chemotherapy.
Topics: Adult; Amantadine; Animals; Antiviral Agents; Drug Therapy; Humans; Influenza, Human; Interferons; Ribavirin; Virus Replication | 1980 |
Antiviral agents for the control of viral diseases.
Topics: Acyclovir; Amantadine; Antiviral Agents; Evaluation Studies as Topic; Guanine; Humans; Interferons; Ointments; Ribavirin; Vidarabine; Virus Diseases; World Health Organization | 1981 |
[Antiviral agents].
Topics: Amantadine; Antiviral Agents; Cytarabine; Humans; Idoxuridine; Interferons; Light; Methisazone; Ribavirin; Rifampin; Viral Proteins; Virus Replication; Viruses | 1981 |
Anti-influenza A activity of combinations of amantadine and ribavirin in ferret tracheal ciliated epithelium.
Topics: Amantadine; Animals; Cilia; Drug Synergism; Epithelium; Ferrets; Influenza A virus; Ribavirin; Ribonucleosides; Trachea; Virus Cultivation | 1983 |
Comparative activity of amantadine and ribavirin against influenza virus in vitro: possible clinical relevance.
Topics: Amantadine; Animals; Dogs; Humans; Influenza, Human; Microbial Sensitivity Tests; Orthomyxoviridae; Ribavirin; Ribonucleosides | 1983 |
Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice.
Topics: Aerosols; Amantadine; Animals; Cell Survival; Drug Therapy, Combination; Immunity, Cellular; Influenza A virus; Injections, Intraperitoneal; Leukocyte Count; Lung; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Ribavirin; Ribonucleosides; Time Factors | 1980 |
Plaque inhibition assay for drug susceptibility testing of influenza viruses.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Microbial; Humans; Influenza, Human; Microbial Sensitivity Tests; Orthomyxoviridae; Ribavirin; Rimantadine; Time Factors; Viral Plaque Assay | 1980 |
Influenza A pneumonitis following treatment of acute cardiac allograft rejection with murine monoclonal anti-CD3 antibody (OKT3).
Topics: Amantadine; Antiviral Agents; Graft Rejection; Heart Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza A virus; Male; Middle Aged; Muromonab-CD3; Pneumonia, Viral; Postoperative Complications; Ribavirin; Virulence | 1995 |
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).
Topics: Amantadine; Animals; Antiviral Agents; Guanidines; Influenza A virus; Influenza B virus; Mice; Neuraminidase; Orthomyxoviridae Infections; Pyrans; Ribavirin; Sialic Acids; Virus Replication; Zanamivir | 1994 |
Drugs for non-HIV viral infections.
Topics: Acyclovir; Amantadine; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Virus Diseases | 1994 |
Combination antiviral therapy for respiratory virus infections.
Topics: Amantadine; Animals; Antiviral Agents; Common Cold; Drug Therapy, Combination; Humans; Influenza, Human; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin; Rimantadine | 1996 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Abnormalities, Drug-Induced; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Contraindications; Cytosine; Drug Resistance, Microbial; Eye Infections, Viral; Famciclovir; Foscarnet; Ganciclovir; Guanine; Humans; Interferon-alpha; Kidney Diseases; Lamivudine; Organophosphonates; Organophosphorus Compounds; Prodrugs; Ribavirin; Rimantadine; Trifluridine; Valacyclovir; Valine; Virus Diseases | 1997 |
Amantadine in the treatment of patients with chronic hepatitis C.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral | 1998 |
Combination therapy for chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 1999 |
Retreatment of hepatitis C patients who do not respond to interferon: the search continues.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Treatment Failure | 2000 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acetamides; Acyclovir; Aged; Amantadine; Animals; Anti-HIV Agents; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Enzyme Inhibitors; Famciclovir; Ganciclovir; Guanidines; Guanine; Herpes Simplex; Herpes Zoster; History, 18th Century; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Lamivudine; Neuraminidase; Oseltamivir; Pyrans; Rats; Ribavirin; Sialic Acids; Teratogens; Valacyclovir; Valine; Zanamivir | 1999 |
Re: Khalili et al.--chronic Hepatitis C treatment in interferon nonresponders.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin | 2000 |
Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Viral Load | 2001 |
Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retreatment; Ribavirin; Treatment Outcome | 2001 |
Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system.
Topics: Amantadine; Animals; Antiviral Agents; Bacteriophage T7; Carcinoma, Hepatocellular; Chlorocebus aethiops; DNA, Complementary; Gene Expression Regulation, Viral; Genes, Synthetic; Hepacivirus; Humans; Interferon-alpha; Liver Neoplasms; Oligodeoxyribonucleotides, Antisense; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Catalytic; RNA, Viral; Terminator Regions, Genetic; Transfection; Tumor Cells, Cultured; Viral Proteins; Virus Replication | 2001 |
Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study.
Topics: Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; Treatment Outcome | 2001 |
Hepatitis C: who should you treat and how?
Topics: Amantadine; Antiviral Agents; Decision Making; Decision Trees; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Diseases; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Protective Agents; Ribavirin; Silymarin | 2001 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Administration, Topical; Amantadine; Animals; Antiviral Agents; Cidofovir; Cytosine; Famciclovir; Foscarnet; Guanine; Herpesviridae Infections; Humans; Influenza, Human; Injections, Intravenous; Lamivudine; Organophosphonates; Organophosphorus Compounds; Rats; Ribavirin; Rimantadine; Thionucleotides; Trifluridine; Valacyclovir; Valine | 2002 |
Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Safety | 2002 |
Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2003 |
The treatment of viral hepatitis, present and future.
Topics: Amantadine; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2004 |
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Biomarkers; Combined Modality Therapy; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Immunotherapy, Active; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-12; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Ribavirin; Statistics, Nonparametric; Tumor Necrosis Factor-alpha; Viral Load | 2004 |
Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon alpha--hype or hope?
Topics: Amantadine; Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure; Treatment Outcome | 2004 |
Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Topics: Adult; Amantadine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; France; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Alignment; Sequence Analysis, DNA; Viral Load | 2005 |
Survival after treatment of rabies with induction of coma.
Topics: Adolescent; Amantadine; Anesthetics; Animals; Antiviral Agents; Athetosis; Benzodiazepines; Bites and Stings; Chiroptera; Chorea; Coma; Dysarthria; Female; Gait Disorders, Neurologic; Humans; Ketamine; Midazolam; Rabies; Rabies virus; Ribavirin | 2005 |
Hepatitis C: are there any options for non-responders?
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2005 |
[Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A].
Topics: Amantadine; Animals; Antiviral Agents; Dogs; Drug Therapy, Combination; Embryo, Mammalian; Indoles; Influenza A virus; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Ribavirin; Virus Replication | 2005 |
[Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis].
Topics: Amantadine; Antiviral Agents; Genotype; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatovirus; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Ribavirin; Viral Load | 2005 |
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; TNF-Related Apoptosis-Inducing Ligand | 2006 |
Influenza virus inhibitors available for the chemotherapy and/or chemoprophylaxis of influenza virus infections.
Topics: Amantadine; Animals; Antibiotic Prophylaxis; Antiviral Agents; Humans; Neuraminidase; Orthomyxoviridae Infections; Ribavirin; Rimantadine | 2006 |
Long-term treatment with the combination of amantadine and ribavirin in hepatitis C nonresponders. A case series.
Topics: Amantadine; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2007 |
Design and synthesis of bioactive 1,2-annulated adamantane derivatives.
Topics: Amantadine; Animals; Antiviral Agents; Drug Design; Influenza A Virus, H3N2 Subtype; Orthomyxoviridae Infections; Ribavirin; Rimantadine; Swine; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African; Viral Matrix Proteins | 2008 |
[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis].
Topics: Amantadine; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Protective Agents; Recombinant Proteins; Ribavirin; Silymarin; Treatment Outcome; Weight Loss | 2008 |
Applying the Milwaukee protocol to treat canine rabies in Equatorial Guinea.
Topics: Amantadine; Anesthetics, Dissociative; Animals; Antiviral Agents; Child, Preschool; Combined Modality Therapy; Dogs; Drug Therapy, Combination; Equatorial Guinea; Fatal Outcome; Humans; Ketamine; Male; Midazolam; Rabies; Rabies virus; Ribavirin; Treatment Outcome; Ubiquinone | 2009 |
Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Humans; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Orthomyxoviridae Infections; Oseltamivir; Ribavirin; Specific Pathogen-Free Organisms; Treatment Outcome | 2009 |
[Peripheral polyneuropathy and bilateral optic neuropathy during treatment of chronic hepatitis C].
Topics: Adrenal Cortex Hormones; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Optic Nerve Diseases; Papilledema; Peripheral Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Vision Disorders | 2009 |
Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Dogs; Drug Synergism; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Orthomyxoviridae; Oseltamivir; Polymerase Chain Reaction; Ribavirin | 2009 |
Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy.
Topics: Adult; alpha 1-Antitrypsin; Amantadine; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Multicenter Studies as Topic; Netherlands; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2010 |
Therapy of rabies encephalitis.
Topics: Adolescent; Amantadine; Animals; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Chiroptera; Clinical Protocols; Combined Modality Therapy; Deep Sedation; Electroencephalography; Encephalitis, Viral; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Midazolam; Phenobarbital; Rabies; Rabies virus; Ribavirin | 2009 |
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Drug Resistance, Viral; Drug Synergism; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Inhibitory Concentration 50; Orthomyxoviridae; Oseltamivir; Ribavirin | 2010 |
Amantadine for treatment of hepatitis C: time to say "enough is enough"?
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2010 |
Application of an In-Cell Western assay for measurement of influenza A virus replication.
Topics: Amantadine; Antiviral Agents; Blotting, Western; Humans; Influenza A virus; Microbial Sensitivity Tests; Nucleocapsid Proteins; Reproducibility of Results; Ribavirin; RNA-Binding Proteins; Time Factors; Viral Core Proteins; Virus Replication | 2010 |
Chronic hepatitis C treatment in näive patients.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Cohort Studies; Critical Illness; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Korea; Male; Middle Aged; Oseltamivir; Pandemics; Respiration, Artificial; Retrospective Studies; Ribavirin; Treatment Outcome | 2011 |
Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus.
Topics: Amantadine; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Influenza A virus; Oseltamivir; Phenotype; Ribavirin; Serial Passage; Suppression, Genetic | 2011 |
Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.
Topics: Amantadine; Animals; Antiviral Agents; Cells, Cultured; Disease Models, Animal; Dogs; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Female; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Placebos; Ribavirin; Treatment Outcome | 2012 |
[Establishment of drug screening assay and pharmacodynamic evaluation method targeting influenza RNA polymerase].
Topics: Alphainfluenzavirus; Amantadine; Antiviral Agents; Drug Evaluation, Preclinical; Genes, Reporter; HEK293 Cells; Humans; Luciferases; Oseltamivir; Plasmids; Reproducibility of Results; Ribavirin; RNA-Dependent RNA Polymerase; Sensitivity and Specificity; Transfection; Zanamivir | 2012 |
Exploration of binary virus-host interactions using an infectious protein complementation assay.
Topics: Amantadine; Animals; Antiviral Agents; Cell Line; Cell Line, Tumor; Copepoda; Cricetinae; DNA-Directed DNA Polymerase; Dogs; Host-Pathogen Interactions; Humans; Influenza A virus; Luciferases; Madin Darby Canine Kidney Cells; Protein Interaction Mapping; Reverse Genetics; Ribavirin; Viral Fusion Proteins; Viral Proteins; Virus Replication | 2013 |
Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Respiratory Distress Syndrome; Ribavirin; Survival Analysis; Treatment Outcome | 2013 |
Treatment of decompensated cirrhosis secondary to hepatitis C with antiviral therapy.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Pakistan; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
[Determination of ribavirin and amantadine in chicken by ultra performance liquid chromatography-tandem mass spectrometry].
Topics: Amantadine; Animals; Chickens; Chromatography, High Pressure Liquid; Food Contamination; Meat; Ribavirin; Tandem Mass Spectrometry | 2013 |
The combination of ribavirin and ozeltamivir effectively inhibits reproduction of influenza A virus resistant to rimantadine (amantadine) in vitro and in vivo.
Topics: Amantadine; Animals; Antiviral Agents; Dogs; Drug Combinations; Drug Resistance, Viral; Influenza A virus; Madin Darby Canine Kidney Cells; Mice; Orthomyxoviridae Infections; Oseltamivir; Ribavirin; Virus Replication | 2014 |
Chromatography column comparison and rapid pretreatment for the simultaneous analysis of amantadine, rimantadine, acyclovir, ribavirin, and moroxydine in chicken muscle by ultra high performance liquid chromatography and tandem mass spectrometry.
Topics: Acyclovir; Amantadine; Animals; Antiviral Agents; Biguanides; Chickens; Chromatography, High Pressure Liquid; Drug Residues; Meat; Morpholines; Ribavirin; Rimantadine; Tandem Mass Spectrometry | 2016 |
A new choice for human rabies diagnosis: A case report of metagenomics next-generation sequencing in diagnosis of human rabies.
Topics: Amantadine; Animals; Dogs; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Pulmonary Edema; Rabies; Ribavirin; Sensitivity and Specificity | 2022 |